Here's Why We're Not At All Concerned With Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Simply Wall StDec 22 22:56

Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $14

Futu NewsDec 21 02:43 · Ratings

Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Announces Target Price $12

Futu NewsDec 19 18:31 · Ratings

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BenzingaDec 19 05:06

Corvus Pharmaceuticals Tumbles Despite Upbeat Comments From CEO -- Market Talk

WSJDec 19 02:49

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

BenzingaDec 19 02:23